Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AI Focus At NHSX Lets Clinicians 'Function At The Top Of Their License'

Executive Summary

Less than 2% of NHS England’s budget is spent on digital technology, compared with 4-5% in other industries, NHS chief information officer Dr. Simon Eccles told delegates at the NHS Health and Care Innovation Expo 2019 this week. But the new NHS AI Lab is seen as a big step in the right direction.

You may also be interested in...



MTI Outlook 2020: Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. AI is now increasingly seen as a realistic solution to demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.  

Opinion: NHSX Will Scale Finite Number Of AI Successes And Avoid Monoculture

UK health care is on the road to AI adoption. It may be a long journey to full implementation, even if the direction of travel is clear, says NHSX chief executive Matthew Gould. 

Luxturna Secures English Reimbursement In Record Time

Novartis/Spark’s Luxturna has been authorized by NICE for use in England after the company agreed a discount on the list price that made the gene therapy cost effective for the national health service. The recommendation was made in record time thanks to good collaboration between the two parties.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel